Paradox of PEGylation in fabricating hybrid nanoparticle-based nicotine vaccines

• Published in: Biomaterials Vol. 182; pp. 72 - 81
• Main Authors: Hu, Yun, Zhao, Zongmin, Harmon, Theresa, Pentel, Paul R., Ehrich, Marion, Zhang, Chenming
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.11.2018
• Subjects: Animals; Drug Delivery Systems - methods; Female; Haptens - administration & dosage; Haptens - immunology; Humans; Hybrid nanoparticle; Immunotherapy; Liposomes - chemistry; Mice; Mice, Inbred BALB C; Nanoparticles - chemistry; Nicotine - immunology; Nicotine vaccine; PEGylation; Polyethylene Glycols - chemistry; Smoking cessation; Smoking Cessation - methods; Stability; Tobacco Use Disorder - immunology; Tobacco Use Disorder - prevention & control; Vaccines - administration & dosage; Vaccines - immunology; Smoking cessation; PEGylation; Stability; Nicotine vaccine; Immunotherapy; Hybrid nanoparticle
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2018.08.015

Polyethylene glycol (PEG) has long been used in nanoparticle-based drug or vaccine delivery platforms. In this study, nano-nicotine vaccines (NanoNicVac) were PEGylated to different degrees to investigate the impact of PEG on the immunological efficacy of the vaccine. Hybrid nanoparticles with various degrees of PEGylation (2.5%–30%) were assembled. It was found that 30% PEGylation resulted in a hybrid nanoparticle of a compromised core-shell structure. A higher concentration of PEG also led to a slower cellular uptake of hybrid nanoparticles by dendritic cells. However, increasing the quantity of the PEG could effectively reduce nanoparticle aggregation during storage and improve the stability of the hybrid nanoparticles. Subsequently, nicotine vaccines were synthesized by conjugating nicotine haptens to the differently PEGylated hybrid nanoparticles. In both in vitro and in vivo studies, it was found that a nicotine vaccine with 20% PEGylation (NanoNicVac 20.0) was significantly more stable than the vaccines with lower PEGylation. In addition, NanoNicVac 20.0 induced a significantly higher anti-nicotine antibody titer of 3.7 ± 0.6 × 104 in mice than the other NanoNicVacs with lower concentrations of PEG. In a subsequent pharmacokinetic study, the lowest brain nicotine concentration of 34 ± 11 ng/g was detected in mice that were immunized with NanoNicVac 20.0. In addition, no apparent adverse events were observed in mice immunized with NanoNicVac. In summary, 20% PEGylation confers NanoNicVac with desirable safety, the highest stability, and the best immunological efficacy in mice. [Display omitted]